| Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia C Blauwendraat, X Reed, L Krohn, K Heilbron, S Bandres-Ciga, M Tan, ... Brain 143 (1), 234-248, 2020 | 201 | 2020 |
| Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes L Greenbaum, K Kanyas, O Karni, Y Merbl, T Olender, A Horowitz, A Yakir, ... Molecular psychiatry 11 (3), 312-322, 2006 | 133 | 2006 |
| SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease RN Alcalay, V Mallett, B Vanderperre, O Tavassoly, Y Dauvilliers, RYJ Wu, ... Movement Disorders 34 (4), 526-535, 2019 | 113 | 2019 |
| Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies L Krohn, TN Öztürk, B Vanderperre, B Ouled Amar Bencheikh, JA Ruskey, ... Annals of neurology 87 (1), 139-153, 2020 | 88 | 2020 |
| Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions L Greenbaum, B Lerer Molecular psychiatry 14 (10), 912-945, 2009 | 87 | 2009 |
| Contribution of genetic variants to pain susceptibility in P arkinson disease L Greenbaum, I Tegeder, Y Barhum, E Melamed, Y Roditi, R Djaldetti European journal of pain 16 (9), 1243-1250, 2012 | 84 | 2012 |
| Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: risk estimates and genotype-phenotype correlations G Yahalom, L Greenbaum, S Israeli-Korn, T Fay-Karmon, V Livneh, ... Parkinsonism & related disorders 62, 179-184, 2019 | 77 | 2019 |
| Association of the Type 2 Diabetes Mellitus Susceptibility Gene, TCF7L2, with Schizophrenia in an Arab-Israeli Family Sample A Alkelai, L Greenbaum, S Lupoli, Y Kohn, K Sarner-Kanyas, E Ben-Asher, ... PloS one 7 (1), e29228, 2012 | 77 | 2012 |
| Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients A Alkelai, L Greenbaum, A Rigbi, K Kanyas, B Lerer Psychopharmacology 206, 491-499, 2009 | 72 | 2009 |
| Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree O Teltsh, K Kanyas-Sarner, A Rigbi, L Greenbaum, B Lerer, Y Kohn International Journal of Neuropsychopharmacology 15 (3), 309-319, 2012 | 70 | 2012 |
| DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population A Alkelai, S Lupoli, L Greenbaum, Y Kohn, K Kanyas-Sarner, E Ben-Asher, ... International Journal of Neuropsychopharmacology 15 (4), 459-469, 2012 | 69 | 2012 |
| Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function A Rigbi, K Kanyas, A Yakir, L Greenbaum, Y Pollak, E Ben‐Asher, ... Genes, Brain and Behavior 7 (2), 164-172, 2008 | 68 | 2008 |
| Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease JA Ruskey, L Greenbaum, L Roncičre, A Alam, D Spiegelman, C Liong, ... European journal of medical genetics 62 (1), 65-69, 2019 | 64 | 2019 |
| Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: serotonergic involvement T Lifschytz, EC Broner, P Zozulinsky, A Slonimsky, R Eitan, L Greenbaum, ... International Journal of Neuropsychopharmacology 15 (9), 1307-1318, 2012 | 62 | 2012 |
| Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication L Greenbaum, RD Strous, K Kanyas, Y Merbl, A Horowitz, O Karni, E Katz, ... Pharmacogenetics and genomics 17 (7), 519-528, 2007 | 52 | 2007 |
| Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia L Greenbaum, A Alkelai, A Rigbi, Y Kohn, B Lerer Movement disorders 25 (16), 2809-2817, 2010 | 49 | 2010 |
| Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region L Greenbaum, RC Smith, A Rigbi, R Strous, O Teltsh, K Kanyas, M Korner, ... The pharmacogenomics journal 9 (2), 103-110, 2009 | 49 | 2009 |
| Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease E Yu, U Rudakou, L Krohn, K Mufti, JA Ruskey, F Asayesh, MA Estiar, ... Movement Disorders 36 (1), 178-187, 2021 | 43 | 2021 |
| Support for association of HSPG2 with tardive dyskinesia in Caucasian populations L Greenbaum, A Alkelai, P Zozulinsky, Y Kohn, B Lerer The pharmacogenomics journal 12 (6), 513-520, 2012 | 42 | 2012 |
| Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations U Rudakou, E Yu, L Krohn, JA Ruskey, F Asayesh, Y Dauvilliers, ... Brain 144 (2), 462-472, 2021 | 40 | 2021 |
